The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells

Journal of Immunology

Volumn 162, Issue 4, 1999, Pages 2281-2290

  Xia, Yu ^a   Větvička, Václav ^a   Yan, Jun ^a   Hanikýřová, Margareta ^a   Mayadas, Tanya ^b   Ross, Gordon D ^a  

^a University of Louisville School of Medicine   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYL MANNOSIDE; ALPHA METHYLGLUCOSIDE; BETA GLUCAN; CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT FACTOR I; GLUCOSE; LECTIN; MANNAN; MANNOSE; METHYL MANNOSIDE; METHYLGLUCOSIDE; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; RECEPTOR; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BINDING SITE; CELL ACTIVATION; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; LIGAND BINDING; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; ANTIGENS, CD18; BINDING SITES; COMPLEMENT C3B; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLUCANS; KILLER CELLS, NATURAL; KINETICS; LECTINS; LEUKEMIA P388; LYMPHOCYTE ACTIVATION; MACROPHAGE-1 ANTIGEN; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, KNOCKOUT; NEUTROPHILS; OPSONIN PROTEINS; PHAGOCYTOSIS; RECEPTORS, IMMUNOLOGIC; SOLUBILITY; ZYMOSAN;

EID: 0345552244     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Nauts, H. C., W. E. Swift, and B. L. Coley. 1946. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 6:205.
2. Diller, I. C., Z. T. Mankowski, and M. E. Fisher. 1963. The effect of yeast polysaccharides on mouse tumors. Cancer Res. 23:201.
3. Chihara, G., Y. Maeda, J. Hamuro, T. Sasaki, and F. Fukuoka. 1969. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 222:687.
4. Di Luzio, N. R., D. L. Williams, R. B. McNamec, B. F. Edwards, and A. Kitahama. 1979. Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Int. J. Cancer 24:773.
5. Williams, D. L., I. W. Browder, and N. R. Di Luzio. 1983. Immunotherapeutic modification of Escherichia coli-induced experimental peritonitis and bacteremia by glucan. Surgery 93:448.
6. Ohno, N., I. Suzuki, S. Oikawa, K. Sato, T. Miyazaki, and T. Yadomae. 1984. Antitumor activity and structural characterization of glucans extracted from cultured fruit bodies of Grifola frondosa. Chem. Pharm. Bull. (Tokyo) 32:1142.
7. Mimura, H., N. Ohno, I. Suzuki, and T. Yadomae. 1985. Purification, antitumor activity, and structural characterization of β-1.3-glucan from Peziza vesiculosa. Chem. Pharm. Bull. (Tokyo) 33:5096.
8. Seljelid, R. 1986. A water-soluble aminated β1-3D-glucan derivative causes regression of solid tumors in mice. Biosci. Rep. 6:845.
9. Kurachi, K., N. Ohno, and T. Yadomae. 1990. Preparation and antitumor activity of hydroxyethylated derivatives of 6-branched (1-3)-β-D-glucan. SSG, obtained from the culture flitrate of Sclerotinia sclerotiorum IFO 9395 Chem. Pharm. Bull. (Tokyo) 38:2527.
10. Kitamura, S., T. Hori, K. Kurita, K. Takeo, C. Kara, W. Itoh, K. Tabata, A. Elgsaeter, and B. T. Stokke. 1994. An antitumor, branched (1→3)-β-D-glucan from a water extract of fruiting bodies of Cryptoporus volvatus. Carbohydr. Res. 263:111.
11. Sveinbjornsson, B., C. Rushfeldt, R. Seljelid, and B. Smedsrod. 1998. Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and β-1.3-D-glucan. Hepatology 27:1241.
12. Mansell, P. W. A., G. Rowden, and C. Hammer. 1978. Clinical experiences with the use of glucan. Prog. Cancer Res. Ther. 7:255.
13. Nakao, I., H. Uchino, K. Orita, I. Kaido, T. Kimura, Y. Goto, T. Kondo, T. Takino, T. Taguchi, T. Nakajima, et al. 1983. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer: a randomized comparative study by an envelop method. Jpn. J. Cancer Chemother. 10:1146.
14. Fujimoto, S., H. Furue, T. Kimura, T. Kondo, K. Orita, T. Taguchi, K. Yoshida, and N. Ogawa. 1984. Clinical evaluation of schizophyllan adjuvant immunoche-motherapy for patients with resectable gastric cancer: a randomized controlled trial. Jpn. J. Surg. 14:286.
15. Wakui, A., M. Kasai, K. Konno, R. Abe, R. Kanamaru, K. Takahashi, Y. Nakai, Y. Yoshida, H. Koie, H. Masuda, et al. 1986 Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group. Jpn. J. Cancer Chemother. 13:1050.
16. Taguchi, T. 1987. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect. Prev. Suppl. 1:333.
17. Fujimoto, S. 1989. Clinical efficacies of schizophyllan (SPG) on advanced gastric cancer. Nippon Geka Gakkai Zasshi 90:1447.
18. Chen, J.-T., and K. Hasumi. 1993. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-γ. Biotherapy 6:189.
19. Tari, K., I. Satake, K. Nakagomi, K. Ozawa, F. Oowada, Y. Higashi, T. Negishi, T. Yamada, H. Saito, and K. Yoshida. 1994. Effect of lentinan for advanced prostate carcinoma. Acta Urol. Jpn. 40:119.
20. Nakano, T., K. Oka, K. Hanba, and S. Morita. 1996. Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer. Clin. Immunol. Immunopathol. 79:79.
21. Matsuoka, H., Y. Seo, H. Wakasugi, T. Saito, and H. Tomoda. 1997. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 17:2751.
22. Cook, J. A., D. Taylor, C. Cohen, J. Rodrique, V. Malshet, and N. R. Di Luzio. 1978. Comparative evaluation of the role of macrophages and lymphocytes in mediating the antitumor action of glucan. Prog. Cancer Res. Ther. 7:183.
23. Amino, M., R. Noguchi, J. Yata, J. Matsumura, R. Hirayama, O. Abe, K. Enomoto, and Y. Asato. 1983. Studies on the effect of lentinan on human immune system. II. In vivo effect on NK activity, MLR induced killer activity and PHA induced blastic response of lymphocytes in cancer patients. Jpn. J. Cancer Chemother. 10:2000.
24. Seljelid, R., J. Bogwald, J. Hoffman, and O. Larm. 1984. A soluble β-1.3-D-glucan derivative potentiates the cytostatic and cytolytic capacity of mouse peritoneal macrophages in vitro. Immunopharmacology 7:69.
25. Sugawara, I., K. C. Lee, and M. Wong. 1984. Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells. I. Characteristics of SPG-treated macrophages. Cancer Immunol. Immunother. 16:137.
26. Morikawa, K., T. Noguchi, M. Yamazaki, and D. Mizuno. 1986. Calcium-dependent and -independent tumoricidal activities of polymorphonuclear leukocytes induced by a linear β-1.3-D-glucan and phorbol myristate acetate in mice. Cancer Res. 46:66.
27. Sherwood, E. R., D. L. Williams, R. B. McNamee, E. L. Jones, I. W. Browder, and N. R. Di Luzio. 1987. In vitro tumoricidal activity of resting and glucan-activated Kupffer cells. J. Leukoc. Biol. 42:69.
28. Suzuki, I., K. Hashimoto, N. Ohno, H. Tanaka, and T. Yadomae. 1989. Immunomodulation by orally administered β-glucan in mice. Int. J. Immunopharmacol. 11:761.
29. Dennert, G., and D. Tucker. 1973. Antitumor polysaccharide lentinan: a T cell adjuvant. J. Natl. Cancer Inst. 51:1727.
30. Hamuro, J., M. Rollinghoff, and H. Wagner. 1978. β(1→3) glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res. 38:3080.
31. Maeda, Y. Y., S. T. Watanabe, C. Chihara, and M. Rokutanda. 1988. Denaturation and renaturation of a β-1,6; 1,3-glucan, lentinan, associated with expression of T-cell-mediated responses. Cancer Res. 48:671.
32. Wagnerova, J., A. Liskova, L. Cervenakova, T. Trnovec, and M. Ferencik. 1991. The immunoadjuvant effect of soluble glucan derivatives in mice. Folia Microbiol. (Praha) 36:198.
33. Suzuki, M., T Kikuchi, F. Takatsuki, and J. Hamuro. 1993. The role of tumor antigen specific delayed-type hypersensitivity responses in eradicating tumors by lentinan. Biotherapy 7:345.
34. 3) for β-glucans. Complement Inflamm. 4:61.
35. Větvička, V., B. P. Thornton, and G. D. Ross. 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or NK cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:50.
36. 2 production but not antigen-presenting function. J Leukoc. Biol. 49:342.
37. Ohno, N., K. Saito, J. Nemoto, S. Kaneko, Y. Adachi, M. Nishijima, T. Miyazaki, and T. Yadomae. 1993. Immunopharmacological characterization of a highly branched fungal (1→3)-β-D-glucan, OL-2, isolated from Omphalia lapidescens. Biol. Pharm. Bull. 16:414.
38. Ljungman, A. G., P. Leanderson, and C. Tagesson. 1998. (1→3)-β-D-glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages. Environ. Toxicol. Pharmacol. 5:273.
39. Thornton, B. P., V. Větvička, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235.
40. Cain, J. A., S. L. Newman, and G. D. Ross. 1987. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement Inflamm. 4:75.
41. Větvička, V., B. P. Thornton, T. J. Wieman, and G. D. Ross. 1997. Targeting of NK cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159:599.
42. Diamond, M. S., J. Garcia-Aguilar, J. K. Bickford, A. L. Corbi, and T. A. Springer. 1993. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol. 120:1031.
43. Lee, J.-O., P. Rieu, M. A. Arnaout, and R. Liddington. 1995. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell 80:631.
44. Xia, Y., and G. D. Ross. 1998. Mapping the β-glucan-binding lectin site of human CR3 (CD11b/CD18) with recombinant fragments of CD11b. FASEB J. 12:A907 (Abstr.).
45. Kadish, J. L., C. C. Choi, and J. K. Czop. 1986. Phagocytosis of unopsonized zymosan particles by trypsin-sensitive and β-glucan-inhibitable receptors on bone marrow-derived murine macrophages. Immunol. Res. 5:129.
46. 3. Immunology 63:319.
47. Goldman, R. 1988. Characteristics of the β-glucan receptor of murine macrophages. Exp. Cell Res. 174:481.
48. Giaimis, J., Y. Lombard, P. Fonteneau, C. D. Muller, R. Levy, M. Makaya-Kumba, J. Lazdins, and P. Poindron. 1993. Both mannose and β-glucan receptors are involved in phagocytosis of unopsonized, heat-killed Saccharomyces cerevisiae by murine macrophages. J. Leukoc. Biol. 54:564.
49. Seljelid, R., L.-T. Rasmussen, O. Larm, J. Hoffman, and L. T. Rasmussen. 1987. The protective effect of β1-3-D-glucan-derivatized plastic beads against Escherichia coli infection in mice. Scand. J. Immunol. 25:55.
50. Konopski, Z., B. Smedsrod, R. Seljelid, and T. Eskeland. 1994. A novel immunomodulator soluble aminated β-1,3-D-glucan: binding characteristics to mouse peritoneal macrophages. Biochim. Biophys. Acta Mol. Cell Res. 1221:61.
51. Okuda, T., and T. Tachibana. 1989. Tumor cell killing by peritoneal exudate macrophages and complement receptors. In New Horizons of Tumor Immunotherapy. M. Torisu and T. Yoshida, eds. Excerpta Medica, Amsterdam, p. 135.
52. Pillemer, L., and E. E. Ecker. 1941. Anticomplementary factor in fresh yeast. J. Biol. Chem. 137:139.
53. 3. J. Clin. Invest. 82:640.
54. Winchester, R. J., and G. D. Ross. 1986. Methods for enumerating cell populations by surface markers using conventional microscopy. In Manual of Clinical Laboratory Immunology. N. R. Rose, H. Friedman and J. L. Fahey, eds. American Society for Microbiology, Washington, DC, p. 212.
55. Fraker, P. J., and J. C. Speck. 1978. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6,-tetrachloro-3a,6a-diphenylglvcoluril. Biochem. Biophys. Res. Commun. 80:849.
56. Rosen, H., S. Gordon, and R. J. North. 1989. Exacerbation of murine listeriosis by a monoclonal antibody specific for the type 3 complement receptor of myelomonocytic cells: absence of monocytes at infective foci allows Lisreria to multiply in nonphagocytic cells. J. Exp. Med. 170:27.
57. 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5:653.
58. Kruisbeek, A. M. 1996. In vitro assays for mouse lymphocyte function. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley & Sons, New York, p. 3.0.5.
59. Ross, G. D. 1981. Assays for macrophage complement and Fc receptors. In Manual of Macrophage Methodology. H. B. Herscowitz, H. T. Holden, J. A. Bellanti, and A. Ghaffar, eds. Marcel Dekker, New York, p. 209.
60. Ross, G. D., V. Větvička, and B. P. Thornton. 1998, Analysis of the phagocyte membrane lectin CR3 (CD11b/CD18) using fluorescence-labeled polysaccharides and flow cytometry. In Phagocyte Functions: A Guide for Research and Clinical Evaluation. J. P. Robinson and G. F. Babcock, eds. John Wiley & Sons, New York, p. 1.
61. Fernandez-Botran, R., V. M. Sanders, and E. S. Vitetta. 1989. Interactions between receptors for interleukin 2 and interleukin 4 on lines of helper T cells (HT-2) and B lymphoma cells (BCL1). J. Exp. Med. 169:379.
62. Takahashi, K., M. J. Donovan, R. A. Rogers, and R. A. B. Ezekowitz. 1998. Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res. 292:311.
63. Bianco, C., F. M. Griffin, Jr., and S. C. Silverstein. 1975. Studies of the macrophage complement receptor: alteration of receptor function upon macrophage activation. J. Exp. Med. 141:1278.
64. Riggi, S. J., and N. R. Di Luzio. 1961. Identification of a reticuloendothelial stimulating agent in zymosan. Am. J. Physiol. 200:297.
65. Janusz, M. J., K. F. Austen, and J. K. Czop. 1986. Isolation of soluble yeast β-glucans that inhibit human monocyte phagocytosis mediated by β-glucan receptors. J. Immunol. 137:3270.
66. Montijn, R. C., J. van Rinsum, F. A. van Schagen, and F. M. Klis. 1994. Glucomannoproteins in the cell wall of Saccharomyces cerevisiae contain a novel type of carbohydrate side chain. J. Biol. Chem. 269:19338.
67. Kollar, R., B. B. Reinhold, E. Petrakova, H. C. Yeh, G. Ashwell, J. Drgonova, J. C. Kapteyn, F. M. Klis, and E. Cabib. 1997. Architecture of the yeast cell wall: β(1→6)-glucan interconnects mannoprotein, β(1→3)-glucan, and chitin. J. Biol. Chem. 272:17762.
68. Forsyth, C. B., and H. L. Mathews. 1996. Lymphocytes utilize CD11b/CD18 for adhesion to Candida albicans. Cell. Immunol. 170:91.
69. Janusz, M. J., K. F. Austen, and J. K. Czop. 1988. Phagocytosis of heat-killed blastospores of Candida albicans by human monocyte β-glucan receptors. Immunology 65:181.
70. Scaringi, L., P. Marconi, M. Boccanera, L. Tissi, F. Bistoni, and A. Cassone. 1988. Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J. Gen. Microbiol. 134:1265.
71. Fradin, C., T. Jouault, A. Mallet, J. M. Mallet, D. Camus, P. Sinaÿ, and D. Poulain. 1996. β-1,2-linked oligomannosides inhibit Candida albicans binding to murine macrophage. J. Leukoc. Biol. 60:81.
72. Jamas, S., D. D. Easson, G. R. Ostroff, and A. B. Onderdonk. 1991. PGG-glucans: a novel class of macrophage-activating immunomodulators. In Polymeric Drugs and Delivery Systems. American Chemical Society, Washington, DC, p. 44.
73. Ohno, N., T. Miura, K. Saito, M. Nishijima, T. Miyazaki, and T. Yadomae. 1992. Physicochemical characteristics and antitumor activities of a highly branched fungal (1→3)-β-D-glucan, OL-2, isolated from Omphalia lapidescens. Chem. Pharm. Bull. (Tokyo) 40:2215.
74. Okazaki, M., Y. Adachi, N. Ohno, and T. Yadomae. 1995. Structure-activity relationship of (1→3)-β-D-glucans in the induction of cytokine production from macrophages, in vitro. Biol. Pharm. Bull. 18:1320.
75. Anderson, D. C., F. C. Schmalstieg, M. A. Arnaout, S. Kohl, M. F. Tosi, N. Dana, G. J. Buffone, B. J. Hughes, B. R. Brinkley, W. D. Dickey, J. S. Abramson, T. Springer, L. A. Boxer, J. M. Hollers, and C. W. Smith. 1984. Abnormalities of polymorphonuclear leukocyte function associated with heritable deficiency of high molecular weight surface glycoproteins (GP138): common relationship to diminished cell adherence. J. Clin. Invest. 74:536.
76. Czop, J. K., and K. F. Austen. 1985. A β-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J. Immunol. 134:2588.
77. 3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J. Immunol. 134:3307.
78. 2 and interleukin 1 by mouse peritoneal macrophages stimulated with β-1,3-D-glucan derivatized plastic beads. Scand. J. Immunol. 26:731.
79. Sakagami, Y., Mizoguchi, T. Shin, S. Seki, K. Kobayashi, S. Morisawa, and S. Yamamoto. 1988. Effects of an anti-tumor polysaccharide, schizophyllan, on interferon-γ and interleukin 2 production by peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 155:650.
80. Tsuchiya, Y., M. Igarashi, M. Inoue, and K. Kumagai. 1989. Cytokine-relaled immunomodulating activities of an anti-tumor glucan, sizofiran (SPG). J. Pharmacobiodyn. 12:616.
81. Abel, G., and J. K. Czop. 1992. Stimulation of human monocyte β-glucan receptors by glucan particles induces production of TNF-α and IL-1β. Int. J. Immunopharmacol. 14:1363.
82. Adachi, Y., M. Okazaki, N. Ohno, and T. Yadomae. 1994. Enhancement of cytokine production by macrophages stimulated with (1→3)-β-D-glucan, Grifolan (GRN). isolated from Grifola frondosa. Biol. Pharm. Bull. 17:1554.
83. Nemoto, J., N. Ohno, K. Saito, Y. Adachi, and T. Yadomae. 1994. Analysis of cytokine mRNAs induced by the administration of a highly branched (1→3)-β-D-glucan, OL-2 analysis of cytokine mRNAs induced by the administration of a highly branched (1→3)-β-D-glucan, OL-2 Biol. Pharm. Bull. 17:948.